Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, an increase in the notional allocation of Ordinary share ADRs occurred on January 21, 2011. The transaction price was $37.35 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items related to the company's operational strategy or financial health. It strictly reports on the compliance notification required by Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- The filing reports a notional increase in ADR allocations for four specific individuals: Dr K Belmonte (4), Mr W C Louv (9), Dr M M Slaoui (19), and Dr D Pulman (14).
- The transaction price for the ADRs was $37.35.
- This is a compliance filing regarding director transactions and does not contain quarterly or annual financial results.